Fanshawe College in Ontario, Canada said on Thursday that its Centre for Research and Innovation has developed a safe, rapid and inexpensive method to identify the effectiveness of potential COVID-19 drug treatments.
Principal investigator Abdulla Mahboob, PhD has created artificial copies of the SARS-COV-2 virus called replicons that can be transferred into mammalian cells. The replicons are non-infectious, with the non-structural genes of the virus but missing the genes allowing the virus to assemble into an infectious agent. This enables testing of new COVID-19 drug therapies against the replicon outside of expensive biosafety level-2 laboratories.
Dr Mahboob's replicon has been developed with two problematic mutations in the current pandemic: one that is associated with higher mortality and another that is resistant against the current treatment remdesivir.
The team is working with the National Institutes of Health in the US to validate a peptide-inhibitor treatment option for COVID-19.
Chugai Pharmaceutical announces first 9 months 2020 financial results
Daiichi Sankyo doses first patient in cancer drug DS-1055 study
Roche and Atea Pharmaceuticals collaborate to develop COVID-19 Oral treatment
Alligator Bioscience to focus on ATOR-1017 and mitazalimab
Independent study finds AstraZeneca's COVID-19 vaccine follows genetic instructions
HemoShear Therapeutics signs research collaboration and service agreement with Takeda Pharmaceutical
Volunteer in Brazil trail of AstraZeneca COVID-19 vaccine trial dies; Trial to continue